Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMT. - Université de Lille Accéder directement au contenu
Article Dans Une Revue Bone Marrow Transplantation Année : 2022

Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMT.

M. Nabergoj
  • Fonction : Auteur
K. Mauff
  • Fonction : Auteur
D. Beelen
  • Fonction : Auteur
A. Ganser
  • Fonction : Auteur
N. Kröger
  • Fonction : Auteur
F. Stölzel
  • Fonction : Auteur
J. Finke
  • Fonction : Auteur
J. Passweg
  • Fonction : Auteur
J. Cornelissen
  • Fonction : Auteur
N. Schub
  • Fonction : Auteur
J. H. Veelken
  • Fonction : Auteur
Y. Beguin
  • Fonction : Auteur
K. Wilson
  • Fonction : Auteur
T. Zuckerman
  • Fonction : Auteur
R. P. Porras
  • Fonction : Auteur
Pascal Turlure
  • Fonction : Auteur
T. Kerre
  • Fonction : Auteur
L. Koster
  • Fonction : Auteur
P. J. Hayden
  • Fonction : Auteur
F. Onida
  • Fonction : Auteur
C. Scheid
  • Fonction : Auteur
Y. Chalandon
  • Fonction : Auteur

Résumé

We performed a registry study on therapy-related myeloid neoplasm (t-MN), both therapy-related myelodysplastic syndrome (t-MDS) and acute myeloid leukemia (t-AML) following treatment for breast cancer who underwent a first allogeneic hematopoietic cell transplant (allo-HCT). Of 252 identified female patients (median age 57 years), 77% were transplanted for t-AML and 23% for t-MDS, with a median time from breast cancer diagnosis to the diagnosis of tMN and subsequent allo-HCT of 3.7 and 4.6 years, respectively. At transplant, 191 patients were in remission for breast cancer, while 4 were not (57 missing). T-MN was in a complete remission at the time of transplant in 67% of patients. 2-year overall survival, relapse free-survival, relapse incidence and non-relapse mortality were 50%, 45%, 33%, and 22%, respectively. Multivariable analysis revealed that if the t-MN was not in CR pre-transplant, this was associated with lower OS, RFS, and a higher relapse incidence. Seventeen cases of breast cancer recurrence were recorded after a median of 2.4 years post-transplant, and relapse of primary breast cancer accounted for 7% of deaths. This study indicates that allo-HCT for t-MN following treatment for breast cancer shows encouraging transplant outcomes. The incidence of breast cancer relapse post-transplant remains a cause for concern.

Dates et versions

hal-04516160 , version 1 (22-03-2024)

Identifiants

Citer

M. Nabergoj, K. Mauff, D. Beelen, A. Ganser, N. Kröger, et al.. Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMT.. Bone Marrow Transplantation, 2022, Bone Marrow Transplantation, 57, pp.1072-1078. ⟨10.1038/s41409-022-01686-7⟩. ⟨hal-04516160⟩
2 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More